Lung Cancer Trial, Recruiting NCT05778253 Sponsor: Second Xiangya Hospital of Central South University Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT05778253
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with lung squamous cell carcinoma (a specific type of lung cancer), confirmed by a laboratory test of tissue or cell samples
  • People aged between 18 and 75 years old
  • People who are willing to take part in the study and sign a consent form
  • People whose lung cancer has not yet been treated
  • People whose cancer is classified as stage II to stage IIIb and has been assessed by doctors as able to be surgically removed, or potentially able to be surgically removed, based on a standard cancer staging system
  • People for whom enough tissue or blood samples are available to meet the study's testing requirements
  • People with a performance score of 0 or 1 on the ECOG scale, which means they are either fully active or have only minor limitations in physical activity (confirm with trial site)

Who may not be able to join:

  • People who are unable to understand what the trial involves or who are unwilling to sign the consent form
  • People whose lung cancer is a non-squamous type
  • People whose stage IIIa to IIIb cancer has been assessed as unable to be surgically removed
  • People who have previously received a solid organ or bone marrow transplant
  • People who have previously been treated with certain immune-based cancer therapies (specifically CTLA-4, PD-1, or PD-L1 inhibitors)
  • People who have a condition involving scarring or inflammation of the lung tissue (interstitial lung disease)
  • People who currently have an active acute or chronic infection
  • People who are pregnant or breastfeeding
  • People who are currently taking part in another clinical drug trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 8685296122

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Second Xiangya Hospital of Central South University
Registry
ClinicalTrials.gov
Start date
23 March 2023
Est. completion
23 September 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Pathologic completet response (pCR) rate; ctDNA resolution; Development of computer algorithm to identify pCR features; Validation of computer algorithm to identify pCR features

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov